<SEC-DOCUMENT>0001019687-16-007141.txt : 20160810
<SEC-HEADER>0001019687-16-007141.hdr.sgml : 20160810
<ACCEPTANCE-DATETIME>20160809200501
ACCESSION NUMBER:		0001019687-16-007141
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		5
CONFORMED PERIOD OF REPORT:	20160809
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20160810
DATE AS OF CHANGE:		20160809

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			RadNet, Inc.
		CENTRAL INDEX KEY:			0000790526
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-MEDICAL LABORATORIES [8071]
		IRS NUMBER:				133326724
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33307
		FILM NUMBER:		161819684

	BUSINESS ADDRESS:	
		STREET 1:		1510 COTNER AVE
		CITY:			LOS ANGELES
		STATE:			CA
		ZIP:			90025
		BUSINESS PHONE:		3104787808

	MAIL ADDRESS:	
		STREET 1:		1510 COTNER AVE
		CITY:			LOS ANGELES
		STATE:			CA
		ZIP:			90025

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PRIMEDEX HEALTH SYSTEMS INC
		DATE OF NAME CHANGE:	19930518

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CCC FRANCHISING CORP
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>radnet_8k-080916.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="margin: 0pt 0"></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>



<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 8-K</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CURRENT REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of Report (Date of earliest event reported
August 9, 2016</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>



<P STYLE="font: 24pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>RADNET, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in
its Charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>



<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 32%; text-align: center">Delaware</td>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</td>
    <TD STYLE="width: 34%; text-align: center">0-19019</td>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</td>
    <TD STYLE="width: 32%; text-align: center">13-3326724</td></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: center"><font style="font-size: 10pt">(State or Other Jurisdiction of Incorporation)</font></td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: center"><font style="font-size: 10pt">(Commission File Number)</font></td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: center"><font style="font-size: 10pt">(IRS Employer Identification No.)</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-weight: normal">1510 Cotner
Avenue </FONT><BR>
<FONT STYLE="font-weight: normal">Los Angeles, California 90025</FONT><BR>
<FONT STYLE="font-size: 10pt; font-weight: normal">(Address of Principal Executive Offices) (Zip Code)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt; font-weight: normal">&nbsp;</FONT><FONT STYLE="font-weight: normal">
</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(310)&nbsp;478-7808<BR>
<FONT STYLE="font-size: 10pt">(Registrant&rsquo;s Telephone Number, Including Area Code)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"></FONT></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">[_] Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">[_] Soliciting material pursuant to Rule 14a-12 under the Exchange
Act (17 CFR 240.14a-12)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">[_] Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b) )</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">[_] Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c) )</P>

<P STYLE="margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo; Options: Hidden -->&nbsp;<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0"><B>Item 2.02&#9;RESULTS OF OPERATIONS AND FINANCIAL CONDITION</B></P>

<P STYLE="margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On August 9, 2016 RadNet,
Inc. (&ldquo;RadNet&rdquo;) issued a press release and held a conference call regarding our financial results for the quarter ended
June 30, 2016. A copy of the press release is furnished as Exhibit 99.1 and a copy of the transcript of the conference call is
furnished as Exhibit 99.2 to this Current Report.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The information in
this Current Report, including Exhibit 99.1 and Exhibit 99.2 is being furnished and shall not be deemed &ldquo;filed&rdquo; for
purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that Section. The information
in this Current Report, including Exhibit 99.1 and Exhibit 99.2 shall not be incorporated by reference into any registration statement
or other document filed with the Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>Item 9.01&#9;FINANCIAL
STATEMENTS AND EXHIBITS.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">(d) Exhibits</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.5in; text-indent: -2.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.5in; text-indent: -2.5in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD><U>Exhibit Number</U></TD>
    <TD><U>Description of Exhibit</U></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 15%">99.1</TD>
    <TD STYLE="width: 85%">Press Release dated August 9, 2016 relating to RadNet, Inc.&rsquo;s financial results for the quarter ended June 30, 2016.</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>99.2</TD>
    <TD>Transcript of conference call.</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.5in; text-indent: -2.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.5in; text-indent: -2.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.5in; text-indent: -2.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.5in; text-indent: -2.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.5in; text-indent: -2.5in"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.5in; text-indent: -2.5in"></P>



<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">SIGNATURE</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pursuant to the requirements of the Securities
Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 50%">Date:&nbsp;&nbsp;August 9, 2016</td>
    <TD STYLE="width: 50%; text-align: left"><b>RADNET, INC.</b></td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD STYLE="text-align: left">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">By:<u> /s/ Jeffrey L. Linden____________ </u></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">Name: Jeffrey L. Linden<br>
        Title: Executive Vice President and General Counsel</P></td></tr>
</table>
<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">EXHIBIT INDEX</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD><B><U>Exhibit No.</U></B></TD>
    <TD><B><U>Description</U></B></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD><B>&nbsp;</B></TD>
    <TD><B>&nbsp;</B></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 15%"><B>99.1</B></TD>
    <TD STYLE="width: 85%"><B>Press Release dated August 9, 2016</B></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD><B>&nbsp;</B></TD>
    <TD><B>&nbsp;</B></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD><B>99.2</B></TD>
    <TD><B>Transcript of conference call.</B></TD></TR>
</TABLE>
<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>radnet_8k-ex9901.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"><B>Exhibit 99.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="image_001.jpg" ALT="" STYLE="height: 70px; width: 164px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">FOR IMMEDIATE RELEASE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><B>RadNet Reports Second Quarter Financial Results and Reaffirms
Previously Announced 2016 Guidance Levels</B></P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="margin-top: 0pt; font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Total Net Revenue, modified for working capital adjustments related
to New York acquisitions, (&ldquo;Adjusted Revenue&rdquo;), increased 10.0% to $224.6 million in the second quarter of 2016 from
$204.3 million in the second quarter of 2015</I></FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="margin-top: 0pt; font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Adjusted EBITDA<SUP>(1)</SUP> increased 4.7% to $35.1 million in
the second quarter of 2016 from $33.5 million in the second quarter of 2015 </I></FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="margin-top: 0pt; font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Sequentially, as compared to the first quarter of 2016, Adjusted
Revenue increased 3.8%, and Adjusted EBITDA<SUP>(1)</SUP> increased 29.6% </I></FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="margin-top: 0pt; font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Earnings Per Share was $0.09 per share, also modified for New York
acquisition-related tax-effective adjustments (&ldquo;Adjusted Earnings Per Share&rdquo;), in the second quarter of 2016, an increase
from $0.08 from the second quarter of 2015</I></FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="margin-top: 0pt; font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Aggregate procedural volumes increased 9.6% and same center volumes
increased 0.4% as compared with the second quarter of 2015</I></FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="margin-top: 0pt; font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Completed successful refinancing of the majority of our debt facilities
on July 1<SUP>st</SUP>, effectively extending maturities and providing additional operating flexibility</I></FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="margin-top: 0pt; font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: windowtext">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Commenced operations of our first health system joint venture in
California with Dignity Health </I></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>LOS ANGELES,
California, August 9, 2016 &ndash; RadNet, Inc. (NASDAQ: RDNT),</B> <FONT STYLE="color: black">a national leader in providing high-quality,
cost-effective, fixed-site outpatient diagnostic imaging services through a network of 310 owned and/or operated outpatient imaging
centers</FONT>, today reported financial results for its second quarter of 2016.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dr. Howard Berger, President and Chief
Executive Officer of RadNet, commented, &ldquo;I am very pleased with our operational results this quarter and the improvements
we are making to our business. Normalizing our results for the one-time non-cash gains and losses in the quarter related to our
New York acquisitions, our business produced double digit revenue growth, positive same store procedural growth for the ninth quarter
in a row and higher EBITDA and Earnings as compared with last year&rsquo;s second quarter. Additionally, sequentially from our
first quarter of this year, our EBITDA increased almost 30%, raising EBITDA margins from 12.5% in the first quarter to 15.6% in
the second quarter of 2016.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dr. Berger continued, &ldquo;I&rsquo;m
excited about the opportunities we have in front of us to continue to expand and improve our business organically, particularly
our ability to leverage best practices of the most successful aspects of our business on the east and west coasts. For example,
we are pursuing several new health system partnerships on the west coast, a business model that has traditionally been a strength
of our east coast operations, and we are looking to expand existing joint ventures on the east coast. During the quarter, we announced
and commenced operations with our first California health system partnership with Dignity Health in the city of Glendale. This
announcement and other initiatives we are working on in California with our Breastlink and oncology capabilities have created keen
interest from other prominent health systems. We are more encouraged than ever that the joint venture partnership model that we&rsquo;ve
successfully demonstrated in the mid-Atlantic and New Jersey marketplaces will become more prominent for our west coast operations
in the coming quarters.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dr. Berger added, &ldquo;Another example
of the sharing of best practices between our east and west coast operations is the opportunity to bring capitation and risk-based
contracting outside of our California marketplace, where it has been such an integral aspect of how we&rsquo;ve successfully grown
our business. Diagnostic Imaging Group, which we acquired last year, had a small risk-based component of its business. With the
combination of DIG&rsquo;s assets with our other significant New York metropolitan operations which include Lenox Hill Radiology,
New York Radiology Partners and our Mid-Rockland Imaging centers, we have begun to initiate meaningful conversations with medical
groups on the east coast interested in our risk-based exclusive network contracting capabilities. I&rsquo;m more confident than
ever that this will be the successful model of the post-Affordable Care Act era, and that RadNet will be the first imaging center
company to meaningfully align with major capitated medical groups, health systems and Accountable Care Organizations across all
of our target markets. We expect to be in a position to discuss these opportunities more meaningfully before year end.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;From a financial perspective, we&rsquo;ve
never been in a stronger position to grow our business. We completed the refinancing of our senior debt facilities on July 1<SUP>st</SUP>,
where we lengthened the maturities on our debt to 2023 (in the case of our first lien term loan) and 2021 in the case of our senior
revolving credit facility. At the same time, we availed ourselves of additional operating flexibility to continue to grow our business
and pursue the types of opportunities for expansion that we envision will be available to us over the next several years. We believe
that securing our capital structure in a low interest rate environment was prudent and allows us to focus on operations without
having concern about risks associated with the capital markets in years to come,&rdquo; finished Dr. Berger.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Second Quarter Financial Results</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the second quarter of 2016, RadNet
reported Adjusted Revenue of $224.6 million, after adding back $6.1 million of one-time non-cash working capital adjustments related
to New York acquisitions which served to lower GAAP Revenue by such an amount during the quarter. Adjusted EBITDA<SUP>(1)</SUP>
for the second quarter was $35.1 million. Adjusted Revenue<SUP> </SUP>increased $20.3 million (or 10.0%) and Adjusted EBITDA<SUP>(1)</SUP>
increased $1.6 million (or 4.7%) from the second quarter of last year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the second quarter, RadNet reported
Adjusted Net Income of $4.4 million, which is modified by removing certain tax effected non-cash items including (i) the $6.1 million
of working capital adjustments mentioned above; (ii) a $5.0 million settlement gain on the return of common stock relating to the
acquisition of Diagnostic Imaging Group; and (iii) a $221,000 one-time adjustment to depreciation in conjunction with the finalization
of the purchase price allocation related to the Diagnostic Imaging Group acquisition. Adjusted Net Income increased $987,000 over
the second quarter of 2015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Per share Adjusted <FONT STYLE="color: black">Net
Income for the second quarter was $0.09, compared to per share Adjusted Net Income in the second quarter of 2015 of $0.08 (based
upon a weighted average number of diluted shares outstanding of 46.9 million and 44.7 million for these periods in 2016 and 2015,
respectively).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: black">Affecting Net
Income in the second quarter of 2016 were certain non-cash expenses and non-recurring items including: $5.0 million settlement
gain related to the return of common stock </FONT>in connection with our acquisition of Diagnostic Imaging Group<FONT STYLE="color: black">;
$6.1 million charge to Revenue related to working capital adjustments also pertaining to acquisitions we completed in New York;
$221,000 of one-time depreciation expense related to the finalization of the purchase price allocation related to the Diagnostic
Imaging Group acquisition; $1.0 million of non-cash employee stock compensation expense resulting from the vesting of certain options
and restricted stock; </FONT>$173,000 of severance paid in connection with headcount reductions related to cost savings initiatives;
$441,000 loss on the sale of certain capital equipment; and <FONT STYLE="color: black">$1.4 million of non-cash amortization of
deferred financing costs and discount on debt issuances.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the second quarter of 2016, as compared
with the prior year&rsquo;s second quarter, MRI volume increased 7.5%, CT volume increased 8.9% and PET/CT volume increased 4.8%.
Overall volume, taking into account routine imaging exams, inclusive of x-ray, ultrasound, mammography and other exams, increased
9.6% over the prior year&rsquo;s second quarter. On a same-center basis, including only those centers which were part of RadNet
for both the second quarters of 2016 and 2015, MRI volume increased 3.0%, CT volume increased 4.4% and PET/CT volume increased
1.3%. Overall same-center volume, taking into account routine imaging exams, inclusive of x-ray, ultrasound, mammography and other
exams, increased 0.4% over the prior year&rsquo;s same quarter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Six Month Financial Results</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the six months ended June 30, 2016,
RadNet reported Adjusted Revenue of $441.0 million, after adding back $6.1 million of one-time non-cash working capital adjustments
related to NY acquisitions which served to lower GAAP Revenue by such an amount during the six month period. Adjusted EBITDA<SUP>(1)</SUP>
for the six month period in 2016 was $62.2 million. Adjusted Revenue<SUP> </SUP>increased $55.4 million (or 14.4%) and Adjusted
EBITDA<SUP>(1)</SUP> increased $8.5 million (or 15.8%) from the same six month period last year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the six month period in 2016, RadNet
reported Adjusted Net Income of $2.6 million, which is modified by removing certain tax effected non-cash items including (i) the
$6.1 million of working capital adjustments mentioned above; (ii) a $5.0 million settlement gain on the return of common stock
relating to the acquisition of Diagnostic Imaging Group; and (iii) a $110,000 one-time adjustment to depreciation in conjunction
with the finalization of the purchase price allocation related to the Diagnostic Imaging Group acquisition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Adjusted Net Income increased $3.8 million
over the six month period of 2015. Per share Adjusted <FONT STYLE="color: black">Net Income for the six month period in 2016 was
$0.06, compared to per share Adjusted Net Loss in the prior year&rsquo;s same period of $(0.03) (based upon a weighted average
number of diluted shares outstanding of 47.0 million and 43.1 million for these periods in 2016 and 2015, respectively).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: black">Affecting operating
results in the </FONT>six months ended June 30, 2016 <FONT STYLE="color: black">were certain non-cash expenses and non-recurring
items including: $5.0 million settlement gain related to the return of common stock </FONT>in connection with the acquisition of
Diagnostic Imaging Group<FONT STYLE="color: black">; $6.1 million charge to Revenue related to a working capital adjustment also
pertaining to acquisitions we completed in New York; $110,000 of one-time depreciation expense related to the finalization of the
purchase price allocation related to the Diagnostic Imaging Group acquisition; $3.8 million of non-cash employee stock compensation
expense resulting from the vesting of certain options and restricted stock; </FONT>$340,000 of severance paid in connection with
headcount reductions related to cost savings initiatives; $441,000 loss on the sale of certain capital equipment; and <FONT STYLE="color: black">$2.7
million of non-cash amortization of deferred financing costs and discount on debt issuances.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>2016 Guidance Update</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">RadNet reaffirms its previously announced
2016 guidance ranges as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; width: 60%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <td colspan="2" style="font-size: 10pt; text-align: justify"><font style="font-size: 10pt">Total Net Revenue (a)</font></td>
    <TD STYLE="font-size: 10pt; text-align: justify"><font style="font-size: 10pt">$870 million - $910 million</font></td></tr>
<TR STYLE="vertical-align: top; background-color: White">
    <td colspan="2" style="font-size: 10pt; text-align: justify"><font style="font-size: 10pt">Adjusted EBITDA</font><sup>(1)</sup></td>
    <TD STYLE="font-size: 10pt; text-align: justify"><font style="font-size: 10pt">$130 million - $140 million</font></td></tr>
<TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <td colspan="2" style="font-size: 10pt; text-align: justify"><font style="font-size: 10pt">Capital Expenditures (b)</font></td>
    <TD STYLE="font-size: 10pt; text-align: justify"><font style="font-size: 10pt">$50 million - $55 million</font></td></tr>
<TR STYLE="vertical-align: top; background-color: White">
    <td colspan="2" style="font-size: 10pt; text-align: justify"><font style="font-size: 10pt">Cash Interest Expense</font></td>
    <TD STYLE="font-size: 10pt; text-align: justify"><font style="font-size: 10pt">$37 million - $40 million</font></td></tr>
<TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <td colspan="2" style="font-size: 10pt; text-align: justify"><font style="font-size: 10pt">Free Cash Flow Generation (c)</font></td>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">$40 million - $50 million</P></td></tr>
<TR STYLE="background-color: White">
    <TD STYLE="width: 27%">&nbsp;</td>
    <TD STYLE="width: 3%">&nbsp;</td>
    <TD STYLE="width: 30%">&nbsp;</td></tr>
</table>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(a)</TD><TD STYLE="text-align: justify">Note the change from prior years. This metric is now presented after the subtraction of bad debt.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(b)</TD><TD STYLE="text-align: justify">Net of proceeds from the sale of equipment, imaging centers and joint venture interests. Represents
an increase of $5 million from originally announced guidance range.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">(c)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Defined by the Company as Adjusted EBITDA</FONT><SUP>(1)</SUP><FONT STYLE="font-size: 10pt">
less total capital expenditures and cash paid for interest. </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dr. Berger added, &ldquo;We are on track
to meet our guidance ranges for the year. All ranges remain unchanged from what we announced earlier in the year with the exception
of increasing our targeted capital expenditure range by $5 million. This increase is to fund a replacement program of our computed
radiography (CR x-ray) scanners to provide them with digital wireless transmitting capabilities. This will improve quality, lower
labor costs and comply with a new CMS ruling which would otherwise lower our x-ray reimbursement from traditional CR systems beginning
in 2018.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Conference Call for Today</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dr. Howard Berger, President and Chief
Executive Officer, and Mark Stolper, Executive Vice President and Chief Financial Officer, will host a conference call to discuss
its second quarter 2016 results on Tuesday, August 9th, 2016 at 7:30 a.m. Pacific Time (10:30 a.m. Eastern Time).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Conference Call Details:</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Date: Tuesday, August 9, 2016</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Time: 10:30 a.m. Eastern Time</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dial In-Number: 888-471-3820</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">International Dial-In Number: 719-325-2388</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">It is recommended that participants dial
in approximately 5 to 10 minutes prior to the start of the 10:30 a.m. call. There will also be simultaneous and archived webcasts
available at <FONT STYLE="font-family: Times New Roman, Times, Serif; color: #2F82DE"><B>http://public.viavid.com/index.php?id=120693</B></FONT>
or http://www.radnet.com under the &ldquo;Investors&rdquo; menu section and &ldquo;News Releases&rdquo; sub-menu of the website.
An archived replay of the call will also be available and can be accessed by dialing 877-870-5176 from the U.S., or 858-384-5517
for international callers, and using the passcode 3424412.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Regulation G: GAAP and Non-GAAP Financial
Information</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This release contains certain financial
information not reported in accordance with GAAP. The Company uses both GAAP and non-GAAP metrics to measure its financial results.
The Company believes that, in addition to GAAP metrics, these non-GAAP metrics assist the Company in measuring its cash-based performance.
The Company believes this information is useful to investors and other interested parties because it removes unusual and nonrecurring
charges that occur in the affected period and provides a basis for measuring the Company's financial condition against other quarters.
Such information should not be considered as a substitute for any measures calculated in accordance with GAAP, and may not be comparable
to other similarly titled measures of other companies. Non-GAAP financial measures should not be considered in isolation from,
or as a substitute for, financial information prepared in accordance with GAAP. Reconciliation of this information to the most
comparable GAAP measures is included in this release in the tables which follow.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif; text-align: justify"><B><I>About RadNet, Inc.</I></B></P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif; text-align: justify">RadNet, Inc. is the leading national provider
of freestanding, fixed-site diagnostic imaging services in the United States based on the number of locations and annual imaging
revenue. RadNet has a network of 310 owned and/or operated outpatient imaging centers. RadNet's core markets include California,
Maryland, Delaware, New Jersey, New York and Rhode Island. In addition, RadNet provides radiology information technology solutions,
teleradiology professional services and other related products and services to customers in the diagnostic imaging industry. Together
with affiliated radiologists, and inclusive of full-time and per diem employees and technicians, RadNet has a total of approximately
7,300 employees. For more information, visit http://www.radnet.com.</P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif; text-align: justify"><B><I>Forward Looking Statements</I></B></P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>This press release contains forward-looking
statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Specifically, statements concerning
successfully integrating acquired operations, successfully achieving 2015 financial guidance, achieving cost savings, successfully
developing and integrating new lines of business, continuing to grow its business by generating patient referrals and contracts
with radiology practices, and receiving third-party reimbursement for diagnostic imaging services, are forward-looking statements
within the meaning of the Safe Harbor. Forward-looking statements are based on management's current, preliminary expectations and
are subject to risks and uncertainties, which may cause the Company's actual results to differ materially from the statements contained
herein. Further information on potential risk factors that could affect RadNet's business and its financial results are detailed
in its most recent Annual Report on Form 10-K, as filed with the Securities and Exchange Commission. Undue reliance should not
be placed on forward-looking statements, especially guidance on future financial performance, which speaks only as of the date
they are made. RadNet undertakes no obligation to update publicly any forward-looking statements to reflect new information, events
or circumstances after the date they were made, or to reflect the occurrence of unanticipated events.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I></I></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I></I></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>CONTACTS:</I></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I></I></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>RadNet, Inc.</I></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Mark Stolper, 310-445-2800</I></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Executive Vice President and Chief
Financial Officer</I></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I></I></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I></I></P>

<P STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">RADNET, INC. AND SUBSIDIARIES</P>

<P STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">CONDENSED CONSOLIDATED BALANCE SHEETS</P>

<P STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">(IN THOUSANDS
EXCEPT SHARE AND PER SHARE DATA)</P>



<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">June 30,</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">December 31,</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">(unaudited)</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="9" STYLE="font-weight: bold; text-align: center">ASSETS</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="font-weight: bold; text-align: left">CURRENT ASSETS</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 66%; text-align: left; padding-left: 10pt">Cash and cash equivalents</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">433</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">446</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-left: 10pt">Accounts receivable, net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">165,086</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">162,843</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Current portion of deferred tax assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">22,278</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">22,279</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-left: 10pt">Due from affiliates</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,273</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,815</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Prepaid expenses and other current assets</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">30,511</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">38,986</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-left: 30pt">Total current assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">222,581</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">229,369</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">PROPERTY AND EQUIPMENT, NET</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">250,426</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">256,722</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="font-weight: bold; text-align: left">OTHER ASSETS</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt">Goodwill</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">240,520</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">239,408</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-left: 10pt">Other intangible assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">44,032</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">45,253</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Deferred financing costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,012</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,841</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-left: 10pt">Investment in joint ventures</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">39,483</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">33,584</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Deferred tax assets, net of current portion</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">24,352</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">24,685</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Deposits and other</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">4,935</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">4,565</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; padding-left: 30pt">Total assets</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">828,341</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">836,427</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="font-weight: bold; text-align: center">LIABILITIES AND EQUITY</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">CURRENT LIABILITIES</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-left: 10pt">Accounts payable, accrued expenses and other</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">108,075</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">113,813</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Due to affiliates</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,545</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,564</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-left: 10pt">Deferred revenue</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,599</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,598</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Current portion of notes payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">21,609</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">22,383</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-left: 10pt">Current portion of deferred rent</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,551</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,563</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Current portion of obligations under capital leases</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">7,713</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">10,038</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 30pt">Total current liabilities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">150,092</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">156,959</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">LONG-TERM LIABILITIES</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-left: 10pt">Deferred rent, net of current portion</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">27,929</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">26,865</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt">Line of credit</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">13,800</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-left: 10pt">Notes payable, net of current portion</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">589,177</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">599,914</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Obligations under capital lease, net of current portion</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,710</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,385</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Other non-current liabilities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">5,667</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">9,843</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 30pt">Total liabilities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">791,375</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">799,966</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="font-weight: bold">EQUITY</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">RadNet, Inc. stockholders' equity:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-left: 22pt; text-indent: -11pt">Common stock - $.0001 par value, 200,000,000 shares authorized;     46,432,404 and 46,281,189
    shares issued and outstanding at June 30, 2016 and December 31, 2015, respectively</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Additional paid-in-capital</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">196,026</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">197,297</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-left: 10pt">Accumulated other comprehensive loss</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(169</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(153</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Accumulated deficit</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(162,669</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(164,571</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-left: 20pt">Total RadNet, Inc.'s stockholders' equity</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">33,192</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">32,577</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Noncontrolling interests</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">3,774</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">3,884</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 30pt">Total equity</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">36,966</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">36,461</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; padding-left: 30pt">Total liabilities and equity</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">828,341</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">836,427</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">RADNET, INC. AND SUBSIDIARIES</P>

<P STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</P>

<P STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">(IN THOUSANDS EXCEPT SHARE DATA)</P>

<P STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">(unaudited)</P>



<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center">Three Months Ended</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center">Six Months Ended</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">June 30,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">June 30,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">NET REVENUE</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="width: 40%; text-align: left; padding-left: 22pt; text-indent: -11pt">Service fee revenue, net of contractual allowances and discounts</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 11%; text-align: right">203,759</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 11%; text-align: right">188,403</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 11%; text-align: right">404,601</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 11%; text-align: right">353,433</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 22pt; text-indent: -11pt">Provision for bad debts</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(12,326</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(8,387</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(22,630</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(15,862</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-left: 22pt; text-indent: -11pt">Net service fee revenue</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">191,433</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">180,016</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">381,971</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">337,571</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 22pt; text-indent: -11pt">Revenue under capitation arrangements</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">27,132</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">24,273</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">52,982</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">47,985</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-left: 22pt">Total net revenue</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">218,565</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">204,289</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">434,953</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">385,556</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">OPERATING EXPENSES</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-left: 22pt; text-indent: -11pt">Cost of operations, excluding depreciation and amortization</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">194,062</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">175,796</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">390,888</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">344,717</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 22pt; text-indent: -11pt">Depreciation and amortization</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">15,811</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">14,941</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">32,223</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">29,235</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-left: 22pt; text-indent: -11pt">Loss on sale and disposal of equipment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">441</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">74</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">441</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">36</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 22pt; text-indent: -11pt">Severance costs</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">173</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">94</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">340</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">130</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-left: 22pt">Total operating expenses</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">210,487</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">190,905</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">423,892</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">374,118</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">INCOME FROM OPERATIONS</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,078</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">13,384</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">11,061</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">11,438</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="font-weight: bold">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">OTHER INCOME AND EXPENSES</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-left: 22pt; text-indent: -11pt">Interest expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,745</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,423</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">21,426</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">20,419</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 22pt; text-indent: -11pt">Meaningful use incentive</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,808</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,270</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-left: 22pt; text-indent: -11pt">Equity in earnings of joint ventures</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,274</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,207</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(5,553</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(4,309</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 22pt; text-indent: -11pt">Gain from return of common stock</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(5,032</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(5,032</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-left: 22pt; text-indent: -11pt">Other expenses</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">4</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">413</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">6</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">410</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 22pt">Total other expenses</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,443</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">7,629</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">8,039</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">13,250</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="font-weight: bold; text-align: left">INCOME (LOSS) BEFORE INCOME TAXES</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,635</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,755</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,022</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,812</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 22pt; text-indent: -11pt">(Provision for) benefit from income taxes</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(2,253</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(2,192</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,073</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">899</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="font-weight: bold; text-align: left">NET INCOME (LOSS)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,382</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,563</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,949</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(913</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 22pt; text-indent: -11pt">Net (loss) income attributable to noncontrolling interests</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(243</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">168</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">47</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">246</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">NET INCOME (LOSS) ATTRIBUTABLE TO RADNET, INC.</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">COMMON STOCKHOLDERS</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">3,625</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">3,395</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,902</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(1,159</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="font-weight: bold">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">BASIC&nbsp;NET INCOME (LOSS) PER SHARE</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">0.08</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">0.08</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">0.04</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.03</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">DILUTED NET INCOME (LOSS) PER SHARE</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-left: 22pt; text-indent: -11pt">ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">0.08</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">0.08</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">0.04</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.03</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold">WEIGHTED AVERAGE SHARES OUTSTANDING</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-left: 22pt; text-indent: -11pt">Basic</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">46,558,944</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">43,370,024</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">46,576,631</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">43,059,686</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 22pt; text-indent: -11pt">Diluted</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">46,882,383</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">44,685,599</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">46,960,226</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">43,059,686</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="margin: 0"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">RADNET, INC. AND SUBSIDIARIES</P>

<P STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</P>

<P STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">(IN THOUSANDS)</P>

<P STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">(unaudited)</P>



<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Six Months Ended June 30,</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;CASH FLOWS FROM OPERATING ACTIVITIES</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="width: 66%; text-align: left; padding-left: 10pt">&nbsp;Net income (loss)</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">1,949</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">(913</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">&nbsp;Adjustments to reconcile net income (loss)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-left: 20pt">&nbsp;to net cash provided by operating activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">&nbsp;Depreciation and amortization</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">32,223</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">29,235</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-left: 10pt">&nbsp;Provision for bad debts</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">22,630</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">15,862</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">&nbsp;Gain from return of common stock</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(5,032</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-left: 10pt">&nbsp;Equity in earnings of joint ventures</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(5,553</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(4,309</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">&nbsp;Distributions from joint ventures</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,098</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,195</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-left: 10pt">&nbsp;Amortization and write off of deferred financing costs and loan discount</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,738</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,631</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">&nbsp;Loss on sale and disposal of equipment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">441</TD><TD STYLE="text-align: left">#</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">36</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-left: 10pt">&nbsp;Stock-based compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,761</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,571</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">&nbsp;Changes in operating assets and liabilities, net of assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-left: 20pt">&nbsp;acquired and liabilities assumed in purchase transactions:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 30pt">&nbsp;Accounts receivable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(24,873</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(19,368</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-left: 30pt">&nbsp;Other current assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,454</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,058</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 30pt">&nbsp;Other assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">220</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,687</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-left: 30pt">&nbsp;Deferred taxes</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">333</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,854</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 30pt">&nbsp;Deferred rent</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,052</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,602</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-left: 30pt">&nbsp;Deferred revenue</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(564</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 30pt">&nbsp;Accounts payable, accrued expenses and other</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">10,983</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(2,423</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 40pt">&nbsp;Net cash provided by operating activities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">51,424</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">27,956</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;CASH FLOWS FROM INVESTING ACTIVITIES</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-left: 10pt">&nbsp;Purchase of imaging facilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(6,603</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(34,407</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">&nbsp;Purchase of property and equipment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(40,267</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(31,649</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-left: 10pt">&nbsp;Proceeds from sale of equipment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">63</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">205</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">&nbsp;Cash distribution from existing JV partner</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">994</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 10pt">&nbsp;Equity contributions in existing and purchase of interest in joint ventures</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(734</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(265</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 40pt">&nbsp;Net cash used in investing activities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(46,547</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(66,116</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;CASH FLOWS FROM FINANCING ACTIVITIES</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">&nbsp;Principal payments on notes and leases payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(6,310</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,969</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-left: 10pt">&nbsp;Proceeds from borrowings</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">74,401</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">&nbsp;Payments on Term Loan Debt</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(12,357</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(11,369</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-left: 10pt">&nbsp;Deferred financing costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(531</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">&nbsp;Net proceeds on revolving credit facility</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">13,800</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(15,300</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-left: 10pt">&nbsp;Distributions paid to noncontrolling interests</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(157</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(613</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 10pt">&nbsp;Proceeds from issuance of common stock upon exercise of options/warrants</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">150</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">594</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 40pt">&nbsp;Net cash (used in) provided by financing activities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(4,874</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">43,213</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;EFFECT OF EXCHANGE RATE CHANGES ON CASH</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(16</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(41</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(13</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,012</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">&nbsp;CASH AND CASH EQUIVALENTS, beginning of period</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">446</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">307</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">&nbsp;CASH AND CASH EQUIVALENTS, end of period</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">433</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">5,319</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">&nbsp;Cash paid during the period for interest</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">18,545</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">18,283</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.95pt 0pt 0; text-align: center; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.95pt 0pt 0; text-align: center; background-color: white"><B>RADNET,
INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.95pt 0pt 0; text-align: center; background-color: white"><B>RECONCILIATION
OF GAAP NET INCOME (LOSS) ATTRIBUTABLE TO RADNET, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.95pt 0pt 0; text-align: center; background-color: white"><B>COMMON SHAREHOLDERS TO ADJUSTED EBITDA<SUP>(1)</SUP></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.25in; text-align: center; background-color: white"><B>(IN THOUSANDS)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.25in; text-align: center; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="5" STYLE="text-align: center">Three Months Ended</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="5" STYLE="text-align: center; border-bottom: Black 1pt solid">June 30,</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">2016</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: center; border-bottom: Black 1pt solid">2015</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="width: 66%; text-align: left">Net Income Attributable to RadNet, Inc. Common Shareholders</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">3,625</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">$</TD>
    <TD STYLE="text-align: right">3,395</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Plus Provision for Income Taxes</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,253</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">2,192</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">Plus Other Expenses (Income)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">413</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Less Gain on Acquisition-Related Return of Common Stock</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(5,032</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&ndash;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">Plus Acquisition-Related Working Capital Adjustment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,072</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&ndash;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Plus Interest Expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,745</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">10,423</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">Plus Severance Costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">173</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">94</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Plus Loss on Sale of Equipment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">441</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">74</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">Plus Depreciation and Amortization</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">15,811</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">14,941</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Plus Non Cash Employee Stock Compensation</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,028</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,017</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-bottom: 2.5pt; padding-left: 44pt"><B>Adjusted EBITDA</B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; font-style: normal; font-variant: normal"><SUP>(1)</SUP></FONT></TD><TD STYLE="font-weight: normal; font-style: normal; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">35,120</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">$</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">33,549</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="5" STYLE="text-align: center">Six Months Ended</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="5" STYLE="text-align: center; border-bottom: Black 1pt solid">June 30,</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">2016</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: center; border-bottom: Black 1pt solid">2015</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="width: 66%; text-align: left">Net Loss Attributable to RadNet, Inc. Common Shareholders</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">1,902</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">$</TD>
    <TD STYLE="text-align: right">(1,159</TD>
    <TD>)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Plus Provision for (Benefit From) Income Taxes</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,073</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">(899</TD>
    <TD>)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">Plus Other Expenses (Income)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">410</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Less Gain on Acquisition-Related Return of Common Stock</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(5,032</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">Plus Acquisition-Related Working Capital Adjustment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,072</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Plus Interest Expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">21,426</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">20,419</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">Plus Severance Costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">340</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">130</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Plus Loss on Sale of Equipment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">441</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">36</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">Plus Depreciation and Amortization</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">32,223</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">29,235</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Plus Non Cash Employee Stock Compensation</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">3,761</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">5,571</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-bottom: 2.5pt; padding-left: 44pt"><B>Adjusted EBITDA</B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; font-style: normal; font-variant: normal"><SUP>(1)</SUP></FONT></TD><TD STYLE="font-weight: normal; font-style: normal; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">62,212</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">$</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">53,743</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">PAYOR CLASS
BREAKDOWN**</P>



<P STYLE="margin: 0">&nbsp;</P>

<TABLE BORDER="0" CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <TD STYLE="width: 35%">&nbsp;</td>
    <TD STYLE="text-align: center; background-color: white; width: 15%">Second Quarter</td>
    </tr>
<tr style="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1pt">&nbsp;</td>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center; background-color: white">2016</td>
    </tr>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD>Commercial Insurance</td>
    <TD STYLE="text-align: right">56.3%</td>
    </tr>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Medicare</td>
    <TD STYLE="text-align: right">19.7%</td>
    </tr>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD>Capitation</td>
    <TD STYLE="text-align: right">11.8%</td>
    </tr>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Workers Compensation/Personal Injury</td>
    <TD STYLE="text-align: right">3.9%</td>
    </tr>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD>Medicaid</td>
    <TD STYLE="text-align: right">3.0%</td>
    </tr>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Other</td>
    <TD STYLE="border-bottom: Black 0.5pt solid; text-align: right">5.4%</td>
    </tr>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD>Total</td>
    <TD STYLE="text-align: right">100.0%</td>
    </tr>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">**Capitation percentage has been calculated based upon its proportion of Revenue Under Capitation Arrangements in the period&nbsp;&nbsp;to</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Service Fee Revenue, Net of Contractual
Allowances and Discounts plus Revenue Under Capitation Arrangements. After deducting the capitation percentage from 100%, all
other payor class percentages are based upon a proportion to global payments received from consolidated imaging centers from that
periods dates of services and excludes payments from hospital contracts, Breastlink, imaging center management fees, eRAD, Imaging
on Call and other miscellaneous revenue.</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><BR CLEAR="ALL">
</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">RADNET PAYMENTS
BY MODALITY *</P>



<P STYLE="margin: 0">&nbsp;</P>

<TABLE BORDER="0" CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: center">Second Quarter</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: center">Full Year</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: center">Full Year</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: center">Full Year</td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="border-bottom: Black 0.5pt solid; text-align: center">2016</td>
    <TD>&nbsp;</td>
    <TD STYLE="border-bottom: Black 0.5pt solid; text-align: center">2015</td>
    <TD>&nbsp;</td>
    <TD STYLE="border-bottom: Black 0.5pt solid; text-align: center">2014</td>
    <TD>&nbsp;</td>
    <TD STYLE="border-bottom: Black 0.5pt solid; text-align: center">2013</td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td></tr>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD>MRI</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD STYLE="text-align: right">34.7%</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD STYLE="text-align: right">35.3%</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD STYLE="text-align: right">36.1%</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD STYLE="text-align: right">36.3%</td>
    <TD STYLE="text-align: right">&nbsp;</td></tr>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>CT</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD STYLE="text-align: right">16.0%</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD STYLE="text-align: right">15.7%</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD STYLE="text-align: right">15.3%</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD STYLE="text-align: right">15.5%</td>
    <TD STYLE="text-align: right">&nbsp;</td></tr>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD>PET/CT</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD STYLE="text-align: right">4.9%</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD STYLE="text-align: right">5.1%</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD STYLE="text-align: right">5.7%</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD STYLE="text-align: right">5.6%</td>
    <TD STYLE="text-align: right">&nbsp;</td></tr>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>X-ray</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD STYLE="text-align: right">9.5%</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD STYLE="text-align: right">9.6%</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD STYLE="text-align: right">10.2%</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD STYLE="text-align: right">10.5%</td>
    <TD STYLE="text-align: right">&nbsp;</td></tr>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD>Ultrasound</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD STYLE="text-align: right">12.5%</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD STYLE="text-align: right">11.5%</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD STYLE="text-align: right">11.1%</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD STYLE="text-align: right">11.0%</td>
    <TD STYLE="text-align: right">&nbsp;</td></tr>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Mammography</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD STYLE="text-align: right">16.1%</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD STYLE="text-align: right">16.4%</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD STYLE="text-align: right">16.5%</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD STYLE="text-align: right">15.7%</td>
    <TD STYLE="text-align: right">&nbsp;</td></tr>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD>Nuclear Medicine</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD STYLE="text-align: right">1.2%</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD STYLE="text-align: right">1.3%</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD STYLE="text-align: right">1.4%</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD STYLE="text-align: right">1.5%</td>
    <TD STYLE="text-align: right">&nbsp;</td></tr>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Other</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD STYLE="border-bottom: Black 0.5pt solid; text-align: right">5.1%</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD STYLE="border-bottom: Black 0.5pt solid; text-align: right">5.1%</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD STYLE="border-bottom: Black 0.5pt solid; text-align: right">3.7%</td>
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD STYLE="border-bottom: Black 0.5pt solid; text-align: right">3.9%</td>
    <TD STYLE="text-align: right">&nbsp;</td></tr>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right; border-top-color: Black; border-top-width: 0.5pt">100.0%</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">100.0%</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">100.0%</td>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: right">100.0%</td>
    <TD>&nbsp;</td></tr>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-decoration: underline; margin-top: 0pt; margin-bottom: 0pt">Note</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">* Based upon global payments received from consolidated Imaging Centers from that year's dates of service.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Excludes payments from hospital contracts, Breastlink, Imaging on Call, eRAD, Center Management Fees and other miscellaneous operating activities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Footnotes</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: windowtext"><SUP>&nbsp;</SUP></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: windowtext"><SUP>(1)</SUP>
The Company defines Adjusted EBITDA as earnings before interest, taxes, depreciation and amortization, each from continuing operations
and adjusted for losses or gains on the sale of equipment, other income or loss, debt extinguishments and non-cash equity compensation.
Adjusted EBITDA</FONT> includes equity earnings in unconsolidated operations and subtracts allocations of earnings to non-controlling
interests in subsidiaries<FONT STYLE="color: windowtext">, and is adjusted for non-cash or extraordinary and one-time events taken
place during the period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: windowtext">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Adjusted EBITDA is reconciled to its nearest
comparable GAAP financial measure. Adjusted EBITDA is a non-GAAP financial measure used as analytical indicator by RadNet management
and the healthcare industry to assess business performance, and is a measure of leverage capacity and ability to service debt.
Adjusted EBITDA should not be considered a measure of financial performance under GAAP, and the items excluded from Adjusted EBITDA
should not be considered in isolation or as alternatives to net income, cash flows generated by operating, investing or financing
activities or other financial statement data presented in the consolidated financial statements as an indicator of financial performance
or liquidity. As Adjusted EBITDA is not a measurement determined in accordance with GAAP and is therefore susceptible to varying
methods of calculation, this metric, as presented, may not be comparable to other similarly titled measures of other companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: windowtext"><SUP>(2)</SUP>
As noted above, the Company defines Free Cash Flow as </FONT>Adjusted EBITDA less total Capital Expenditures (whether completed
with cash or financed) and Cash Interest paid. <FONT STYLE="color: windowtext">Free Cash Flow is a non-GAAP financial measure.
</FONT>The Company uses Free Cash Flow because the Company believes it provides useful information for investors and management
because it measures our capacity to generate cash from our operating activities. Free Cash Flow does not represent total cash flow
since it does not include the cash flows generated by or used in financing activities. In addition, our definition of Free Cash
Flow may differ from definitions used by other companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Free Cash Flow should not be considered
a measure of financial performance under GAAP, and the items excluded from Adjusted EBITDA should not be considered in isolation
or as alternatives to net income, cash flows generated by operating, investing or financing activities or other financial statement
data presented in the consolidated financial statements as an indicator of financial performance or liquidity. As Adjusted EBITDA
is not a measurement determined in accordance with GAAP and is therefore susceptible to varying methods of calculation, this metric,
as presented, may not be comparable to other similarly titled measures of other companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 11; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>radnet_8k-ex9902.htm
<DESCRIPTION>TRANSCRIPT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; color: #00339A"><FONT STYLE="color: Black"><B>Exhibit
99.2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; color: #00339A">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; color: #00339A"><IMG SRC="image_002.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; color: #00339A"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; color: #00339A"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; color: #00339A">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; color: #00339A">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; color: #00339A"><B>C O R P O R A T E P A R
T I C I P A N T S</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; color: #00339A"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; color: #00339A"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Mark D. Stolper, </B><I>Executive Vice
President and Chief Financial Officer</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Dr. Howard Berger, </B><I>President
and Chief Executive Officer</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; color: #00339A"><B>C O N F E R E N C E C A
L L P A R T I C I P A N T S</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; color: #00339A"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; color: #00339A"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Brian Tanquilut, </B><I>Jefferies &amp;
Company, Inc.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Per Ostlund, </B><I>Craig-Hallum Capital
Group, LLC</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Juan Molta, </B><I>B. Riley &amp; Co.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Mitra Ramgopal, </B><I>Sidoti &amp;
Co., LLC</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Alan Weber, </B><I>Robotti &amp; Company
Advisors, LLC</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: #00339A"><B>P R E
S E N T A T I O N</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: #00339A"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: #00339A"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Operator:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Good day, and welcome to the RadNet, Inc.
Second Quarter 2016 Financial Results Conference Call. Today's conference is being recorded.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At this time, I would like to turn the
conference over to Mr. Mark Stolper, Executive Vice President and Chief Financial Officer of RadNet, Inc. Please go ahead, Sir.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Mark D. Stolper:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Thank you. Good morning, ladies and gentlemen,
and thank you for joining Dr. Howard Berger and me today to discuss RadNet's second quarter 2016 financial results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Before we begin today, we&rsquo;d like
to remind everyone of the Safe Harbor statement under the Private Securities Litigation Reform Act of 1995. This presentation contains
forward-looking statements within the meaning of the US Private Securities Litigation Reform Act of 1995. Specifically, statements
concerning anticipated future financial and operating performance, RadNet's ability to continue to grow the business by generating
patient referrals and contracts with radiology practices, recruiting and retaining technologists, receiving third-party reimbursement
for diagnostic imaging services, successfully integrating acquired operations, generating revenue and Adjusted EBITDA for the acquired
operations as estimated, among others, are forward-looking statements within the meaning of the Safe Harbor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><IMG SRC="image_002.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Forward-looking statements are based on
Management's current preliminary expectations and are subject to risks and uncertainties, which may cause RadNet's actual results
to differ materially from the statements contained herein. These risks and uncertainties include those risks set forth in RadNet's
reports filed with the SEC from time-to-time, including RadNet's Annual Report on Form 10-K for the year ended December 31, 2015
and RadNet&rsquo;s quarterly report on Form 10-Q to be filed shortly. Undue reliance should not be placed on forward-looking statements,
especially guidance on future financial performance, which speaks only as of the date it is made. RadNet undertakes no obligation
to update publicly any forward-looking statements to reflect new information, events or circumstances after the date they were
made or to reflect the occurrence of unanticipated events.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">With that, I'd like to turn the call over
to Dr. Berger.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Dr. Howard Berger:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Thank you, Mark. Good morning, everyone,
and thank you for joining us today. On today's call, Mark and I plan to provide you with highlights from our second quarter 2016
results, give you more insight into factors which affected this performance, and discuss our future strategy. After our prepared
remarks, we will open the call to your questions. I'd like to thank all of you for your interest in our Company and for dedicating
a portion of your day to participate in our conference call this morning.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Overall, I am encouraged by the improvement
in our metrics and financial performance compared with last year's same quarter and the first quarter of this year. Our adjusted
revenue increased 10% and our Adjusted EBITDA increased 4.7% over last year's second quarter. Procedural volumes increased 9.6%
on an aggregate basis and 0.4% on a same-center basis relative to the second quarter of last year. This was the ninth quarter in
a row that we have experienced positive same-center procedural growth, which is a major factor in driving long-term profitability
and margin enhancement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Adjusted earnings and earnings per share
also increased quarter over same quarter. Sequentially, the quarter was a significant improvement over the first quarter of this
year. Our adjusted revenue increased 3.8% and our Adjusted EBITDA increased almost 30% as compared with the first quarter of 2016.
We turned a net loss of $1.7 million in the first quarter of 2016 into a net profit of $4.4 million in the second quarter. Also
encouraging was that our operating expense ratio dropped from 91% of revenue in the first quarter of this year to 86.4% in the
second quarter, which is a function of operating leverage from increased business and continued focus on cost containment opportunities.
As a result, our EBITDA margin increased from 12.5% in the first quarter of 2016 to 15.6% in the second quarter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our business continues to improve on both
coasts. On the West Coast, we continue to work through some of the capacity issues we faced last year with the unprecedented growth
in our Capitation business and the unique utilization characteristics experienced with the incremental patient populations for
which we've assumed responsibility, particularly those in expanded managed Medicaid programs. We've also commenced operations at
our first significant health system partnership in Glendale, California, with Dignity Health, one of the largest companies in the
Western part of the United States. We are encouraged by the opportunities we are seeing to establish additional partnerships in
the West with other prominent health systems.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We believe this is the result of our continuing
growth and visibility in the communities in which we serve, as well as other capabilities we have built, including oncology and
breast disease management. I am hopeful that before year-end we will be in a position to announce additional partnerships like
we now have with Dignity Health.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the East, the continuing focus and accomplishments
have been surrounding the successful integration of recently acquired entities in the Tristate New York area, particularly the
assets acquired of Diagnostic Imaging Group, New York Radiology Partners, and Lenox Hill Radiology. The significant presence we
have created in the New York Tristate area has placed us in a position where we are negotiating rate increases from certain private
payers and health plans, and has sparked conversations with some of the larger medical groups in this region regarding network
contracting and capitation arrangements. We are hopeful that we will be in a position to announce one or more unique contracting
arrangements by year-end whereby we would bring full risk-based contracting to our East Coast operations in a meaningful way for
the first time in the Company's history.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><IMG SRC="image_002.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the quarter, we had several financial
adjustments related to these acquired New York entities, which Mark will discuss in more detail during his prepared remarks. These
adjustments included those made to adjust for a settlement gain related to the return of common stock we issued in conjunction
with the Diagnostic Imaging acquisition, out-of-period depreciation expenses related to the finalization of purchase accounting
also related to Diagnostic Imaging Group, and working capital modifications related to the acquired New York assets. After making
these adjustments, we are comfortable that these acquired assets are poised for growth and profit improvement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are also working in our East Coast operations
on opportunities to bring our Breast Oncology business to our New York marketplace. Breast Link, up to this point, has been exclusively
expanding in Southern California; however, the opportunities and benefit that it brings to breast disease management and patient
care is universal. We seek by year-end to establish a platform for this type of operation in one of our larger East Coast core
markets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Another focus of ours is to profitably
expand the Barnabas Health joint venture in New Jersey. Our relationship with Barnabas is stronger than ever. We are evaluating
expansion opportunities for the joint venture to include tuck-in acquisitions, building one or more facilities, and exploring additional
opportunities with existing Barnabas hospitals and outpatient operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Another area of potential growth for us
is regarding Inpatient Radiology with existing and new hospital partners. In the past, we have worked with our contracted and affiliated
radiology groups to staff the professional component utilized in hospitals with whom we have partnerships and outpatient imaging
centers. We are now exploring opportunities where we would assume full operating responsibility for both the technical operations
of the inpatient facility, as well as the professional radiology interpretation. We are excited about this as it represents an
expansion opportunity for us with both existing hospital relationships in our core markets, as well as hospitals outside of our
existing operating geographies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Finally, on the cost savings front, we
continue to work on initiatives to capitalize on our scale by making our business more efficient. For instance, we are in the process
of centralizing our insurance preauthorization function for all of our operations, East and West. We are also beginning tests for
online appointment scheduling. Automating these functions will reduce the cost that we currently spend on call centers and patient
service coordinators. We also continue to work with suppliers and other vendors on programs to lower the cost of disposables, such
as contrast agents. Lastly, we are continuing to design programs to lower our cost of equipment repairs and maintenance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At this time, I'd like to turn the call
back to Mark to discuss some of the highlights of our second quarter 2016 performance. When he is finished, I will make some closing
remarks.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Mark D. Stolper:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Thank you, Howard. I'm now going to briefly
review our second quarter 2016 performance and attempt to highlight what I believe to be some material items. I will also give
some further explanation of certain items in our financial statements, as well as provide some insights into some of the metrics
that drove the second quarter performance. Lastly, I will update 2016 financial guidance levels.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In my discussion, I will use the term Adjusted
EBITDA, which is a non-GAAP financial measure. The Company defines Adjusted EBITDA as earnings before interest, taxes, depreciation,
and amortization, each from continuing operations, and excludes losses or gains on the disposal of equipment, other income or loss,
loss on debt extinguishments, bargain purchase gains, and non-cash equity compensation. Adjusted EBITDA includes equity earnings
and unconsolidated operations and subtracts allocations of earnings to non-controlling interest in subsidiaries and is adjusted
for non-cash or extraordinary and one-time events taking place during the period. A full quantitative reconciliation of Adjusted
EBITDA to net income or loss attributable to RadNet, Inc. common Shareholders is included in our earnings release.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><IMG SRC="image_002.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">With that said, I'd now like to review
our second quarter 2016 results. For the three months ended June 30, 2016, RadNet reported adjusted revenue and Adjusted EBITDA
of $224.6 million and $35.1 million, respectively. Adjusted revenue increased $20.3 million or 10% over the prior-year same quarter
and Adjusted EBITDA increased $1.6 million or 4.5% over the prior-year same quarter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the quarter, we booked several non-cash
entries related to adjustments pertaining to acquisitions we made in New York. Specifically, we recognized a $5 million settlement
gain related to the return of common stock pertaining to our acquisition of Diagnostic Imaging Group. As some of you may recall,
we issued to the seller in connection with the acquisition of DIG, 1.5 million RadNet shares. The return of $5 million worth of
these shares relates to a billing issue which we identified subsequent to DIG's purchase. Also, as it relates to DIG and other
acquired New York entities, we made a working capital adjustment of $6.1 million, which from an accounting perspective was charged
against revenue in the current period, effectively reducing our revenue in the quarter by $6.1 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Finally, as it relates to out-of-period
non-cash charges pertaining to New York operations, we made a $221,000 catch-up depreciation entry in the second quarter, which
resulted from the finalization of our purchase price allocation completed by our outside valuation firm, which resulted in a write
up of the acquired assets, and therefore an increase to depreciation resulting since the acquisition date of October 1, 2015. Thus,
in order to evaluate our true operating performance during the quarter, we have adjusted our revenue and EBITDA and earnings metrics
to include&mdash;to exclude these accounting entries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the second quarter of 2016 as compared
to the prior-year second quarter, MRI volume increased 7.5%, CT volume increased 8.9%, and PET CT volume increased 4.8%. Overall
volume, taking into account Routine Imaging Exams, inclusive of x-ray, ultrasound, mammography, and all other exams, increased
9.6% over the prior-year second quarter. In the second quarter of 2016, we performed 1,567,115 total procedures. The procedures
were consistent with our multimodality approach whereby 77.9% of all the work we did by volume was from Routine Imaging.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our procedures in the second quarter of
2016 were as follows. Please note that starting the third quarter of last year of 2015 and including this second quarter, we standardized
our procedural volume categorization among regions according to our internal KBI, or Key Business Indicators dashboard. So the
volumes I'll be quoting for last year's comparison period will be slightly different than those I reported at this time last year.
Because the restated procedural volumes for last year's period are calculated under the same methodology as the current period,
the comparisons between the two periods are accurate, as are the conclusions that can be drawn. Here are the numbers: 193,423 MRIs
as compared to 179,973 MRIs in the second quarter of 2015; 146,947 CTs as compared with 134,974 CTs in the second quarter of 2015;
6,568 PET CTs as compared with the 6,267 PET CTs in the second quarter of 2015; and 1,220,177 Routine Imaging Exams versus 1,109,082
of all these exams in the second quarter of 2015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the second quarter of 2016, RadNet
reported adjusted net income of $4.4 million, which is modified by removing the tax affected non-cash items that I already discussed
included $6.1 million of the working capital adjustments, $5 million settlement gain on the return of the common stock associated
with the Diagnostic Imaging Group acquisition, and the $221,000 one-time adjustment to depreciation in conjunction with the finalization
of the purchase price allocation related to the Diagnostic Imaging Group acquisition. Adjusted net income increased $987,000 over
the second quarter of 2015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><IMG SRC="image_002.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Per share adjusted net income for the second
quarter was $0.09 per share compared to adjusted net income in the second quarter of 2015 of $.08 per share based upon weighted
average number of diluted shares outstanding of 46.9 million and 44.7 million shares for these periods in 2016 and 2015, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Affecting net income in the second quarter
of 2016, were certain non-cash expenses and nonrecurring items, including the $5 million settlement gain related to the DIG acquisition,
the $6.1 million charge to revenue related to the working capital adjustments pertaining to the New York acquisitions, the $221,000
depreciation expense catch-up recorded in the period, $1 million of non-cash employee stock compensation expense resulting from
the vesting of certain options and restricted stock, $173,000 of severance paid in connection with headcount reductions related
to cost savings initiatives, $441,000 loss on the sale of certain capital equipment, and $1.4 million of non-cash amortization
of deferred financing costs and discount on debt issuances.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Overall, GAAP interest expense for the
second quarter of 2016 was $10.7 million. This compares with GAAP interest expense in the second quarter of 2015 of $10.4 million.
At June 30, 2016, after giving effect to bond and term loan discounts, we had $636.6 million of net debt, which is total debt less
our cash balance, and we were drawn $13.8 million on our revolving credit facility which has a capacity of $117.5 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the quarter, we repaid $9.3 million
of notes and leases payable and term loan debt, and had cash capital expenditures net of asset dispositions of $17.7 million. Since
December 31, 2015, accounts receivable increased approximately $2.2 million and our net Days Sales Outstanding, or DSOs, were 63.15
days, a decrease of approximately 2.8 days since year-end 2015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At this time I'd like to reaffirm our 2016
financial guidance levels, which we released in conjunction with our fourth quarter and year-end 2015 results. For total net revenue,
our guidance range is between $870 million and $910 million; our Adjusted EBITDA range is between $130 million and $140 million;
our capital expenditure range is between $50 million and $55 million; our cash interest expense range is between $37 million and
$40 million; and our free cash flow generation range, which we define as our Adjusted EBITDA less total capital expenditures, less
cash paid for interest, the range is $40 million to $50 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are on track to meet our guidance ranges
for the year. All ranges remained unchanged from what we announced earlier in the year with the exception of increasing our targeted
capital expenditure range by $5 million. This increase is to fund a replacement program for our computed radiography, or CT x-ray
scanners, to provide them with digital wireless transmitting capabilities. This will improve quality, lower labor costs, and comply
with a new CMS ruling which would otherwise lower our x-ray reimbursement from traditional CR systems beginning in 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I'll now take a few minutes to give you
an update on 2017 reimbursement and discuss what we know with regards to 2017 anticipated Medicare rates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">With respect to 2017 Medicare reimbursements,
we recently received a matrix for proposed rates by CPT code, which is typically part of the physician fee schedule proposal that
is released about this time every year. We have completed an initial analysis and compared those rates to 2016 rates. We volume
weighted our analysis using expected 2017 procedural volumes. Our initial analysis shows that the Medicare rates for 2017 are essentially
neutral relative to 2016 rates. There are few material changes proposed for 2017 and we estimate no material impact to RadNet's
revenue for 2017. We are obviously very pleased with this as this is only the second year since the advent (phon) of the Deficit
Reduction Act in 2007 where CMS is proposing to leave rates essentially unchanged.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our industry has been significantly impacted
by rate cuts, and we've consistently had to improve our business, in some cases dramatically, just to stay in place. Of course,
the proposed rates for the physician fee schedule are subject to comment from lobbying and industry groups and there's no assurance
the final rule to be released in November 2016 timeframe will reflect these same proposed rates. Whether or not the final rule
in the November timeframe is consistent with the proposed rates, as Dr. Berger discussed earlier in his comments, we will continue
to focus on lowering our cost structure through using our scale and ability to drive efficiencies in our Organization. We will
continue to seek pricing increases in regions where we are essential to the healthcare delivery system, recognizing that our prices
remain significantly discounted as compared to hospital settings. We will also continue to pursue partnership opportunities with
local hospitals and health systems where we think these arrangements could result in increased volumes and long-term stable pricing
from private payers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><IMG SRC="image_002.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Lastly, we will continue to acquire strategic
targets opportunistically at three to four times EBITDA in our core geographies that further our strength in local markets and
achieve efficiencies with our existing operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I'd now like to turn the call back to Dr.
Berger who will make some closing remarks.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Dr. Howard Berger:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Thank you, Mark. Healthcare remains an
exciting and dynamic place to be. The landscape is rapidly changing and it is being reshaped by the effects of the Affordable Care
Act and from the consolidation that has ensued. The Healthcare industry is transforming from a cottage mom-and-pop industry to
one where scale and vertical integration is becoming requisite for long-term survival and success. Today more than ever, the lines
are being blurred between payers and providers. Insurance companies continue to purchase providers in medical groups. Hospitals
are aligning with physician practices and ambulatory and outpatient service providers, such as surgery centers, physical therapy
centers, long-term care facilities, and imaging to name a few. Risk-based contracting is becoming more prevalent with physicians,
hospitals, and other providers assuming financial risk for patient care.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Diagnostic Imaging will continue to play
a central role in healthcare. Its effectiveness and widespread acceptance have and will continue to be the reasons why major providers
and payers will need access to and desire to partner with high quality imaging operators. Imaging, along with other diagnostic
tests, such as those performed by clinical laboratories, are used at the front end of almost every injury or disease process and
healthcare today. Imaging interfaces with all disciplines of medicine, from general internal medicine practices to specialty practice,
such as orthopedics, pediatrics, OB/GYN, cardiology, neurology, nephrology, and the list goes on. These trends give me optimism
and strong convictions (phon) about the future opportunities for RadNet. The trends are working with us and we intend to capitalize
on all opportunities in the changing healthcare landscape we believe can create significant bag for all of our Stakeholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Operator, we are now ready for the question-and-answer
portion of the call.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Operator:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Thank you. If you'd like to ask a question,
please press star, one on your touchtone phone. Please be sure you are unmuted so your signal reaches our equipment. Again, star,
one if you'd like to ask a question. We'll go first to Brian Tanquilut of Jeffries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Brian Tanquilut:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Hey. Good morning, guys. Howard, just as
we think about Capitation, how should we size the Capitation opportunity on the East Coast and how would that impact 2016 results?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><IMG SRC="image_002.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Dr. Howard Berger:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I think they're unlikely to impact the
2016 results. By the way, good morning, Brian. As we are in the process of evaluating these opportunities and are probably way
off before we can announce anything more definitive, we would expect that they might influence our 2017 results, which would be
reflected in the earnings call and guidance that we would give at the end of the first quarter. That being said, what's interesting
about this is that the opportunities, I think, on the East Coast come with perhaps greater opportunity for revenue and driving
volume into our centers more so than the West Coast on a contract-by-contract basis because we're dealing with larger payers and
medical groups than we traditionally see on the West Coast here, which tends to be the smaller medical groups for the most part.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">So, while I can't give you any definitive
information surrounding those discussions as yet, the additional component that we're excited about is that we also expect the
reimbursement for Capitation, given probably higher utilization on the East Coast than the West Coast, to disproportionately benefit
us from a revenue opportunity standpoint.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Brian Tanquilut:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Got it. That makes sense. Howard, as you
think about Barnabas&mdash;you've been with them for a little bit now. What have you learned from that that you can extrapolate
to future partnerships in terms of the differences in operating the business and also how you mind the opportunity as you partner
with a large health system like that? I mean, what have you&mdash;I mean, what can we think of as the opportunity set (phon) or
the pitch for future partnerships going forward?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Dr. Howard Berger:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Well, I think what we've learned is something
that we intuitively knew, but have been able now to put into practice, and that is that hospitals really are not sophisticated
or that deep in their understanding of how to operate the imaging assets. What we've seen particularly in the Barnabas circumstance
is that taking over, I think at this point, three of their on-campus outpatient imaging centers and turning them from money-losing
operations to significantly contributing profitability has demonstrated to the Barnabas Management that their knowledge of imaging
is somewhat at a deficit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I don't believe that this is unique to
imaging because in the case of Barnabas, I think they're recognizing that other ambulatory services, such as surgery centers and
lab, they're continuing to look at outsourcing of those to people who have those management and expertise. What I believe this
will present to us in which we are in the very early discussions of, is turning, as I mentioned in my remarks, to looking at the
inpatient delivery side of this. The joint venture that we have gives us an opportunity to bring perhaps the focus of inpatient
operations through the joint venture and thereby benefiting both parties from any efficiencies that we can potentially bring to
their operations, as well as potentially looking at these assets as another site for us to deliver outpatient imaging and essentially
increasing our access in that marketplace.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">So, I think the Barnabas example will put
us in a very good position for them to be a reference for us to other hospital systems that we're currently in the early stages
of discussions, as well as now that they themselves are growing rapidly&mdash;as you may know, Brian, they've merged with the Robert
Wood Johnson system and so there's 14 hospitals currently in the Barnabas system and, I dare say, that's probably going to grow.
So I think Barnabas will continue more and more to look at us as a solution for all of their imaging opportunities, which will
begin to, I think, focus not only on the outpatient marketplace but also perhaps with some unique opportunities on the inpatient
side.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Brian Tanquilut:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Thanks for that color, Howard. Then, Mark,
bad debt was up quarter-to-quarter. Anything to call out there? Then second question for you: given the expectation for flat Medicare
rates next year, is it safe to assume that we should be expecting some margin expansion next year?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><IMG SRC="image_002.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Mark D. Stolper:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We certainly hope for the margin expansion.
Obviously having flat rates for CMS, which is about 20% of our business, allows us an opportunity to where we're starting off neutral
next year as opposed to starting off in a hole. We're working on some payer increases on the East Coast in the New York Metropolitan
area where we've, in the last 12 to 18 months, built significant scale. So we think that there is a possibility for some net-net
reimbursement increase next year. Then also we have Capitation increases that will kick in as well next year as contracts reach
their annual renewals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">So, we are hopeful that with some reimbursement
increases on a net basis, as well as the continued cost savings initiatives that we have here with respect to online scheduling
and working with some of our vendors using our scale to procure disposables and contrast materials at a lower price, we think that
there really is some opportunity next year for some margin expansion. Also, we're still integrating the Diagnostic Imaging Group
acquisition with our other New York assets that we purchased in the last couple of years and think that there's some upside opportunity
there. So, we are hopeful that we can see some modest margin expansion next year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Brian Tanquilut:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Margin bad debt?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Mark D. Stolper:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Yes. Bad debt, I wouldn't draw any conclusions
from the second quarter here. There was a little bit of a write-down associated with some AR associated with the Diagnostic Imaging
Group acquisition that had to do with a payer, which was also tied into the return of purchase considerations associated with that
acquisition, and that, just from a statistical standpoint, created a little blip in the way we calculate bad debt. But I expect
that to normalize over the coming quarters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Brian Tanquilut:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All right. Got it. Thanks, guys.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Dr. Howard Berger:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Thanks, Brian.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Operator:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Thank you. We'll take our next question
from Per Ostlund of Craig-Hallum Capital Group.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Per Ostlund:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Thanks. Good morning, guys. Actually, want
to follow up on the most recent comments there on the New York properties with DIG and the New York Radiology Partners acquisitions.
Just curious if you can kind of characterize, I guess, the performance of those facilities since acquisition. I think those have
kind of been in the system here for anywhere from, what, two to four, five quarters now. How are they performing from a top line
standpoint and maybe where are they at in the integration process? Are they approaching RadNet kind of Company margins yet or do
we still have a ways to go? Then I guess related to that is: were any the adjustments announced today&mdash;were any of those gating
factors that maybe kept&mdash;that maybe held the integration back at all? Thanks.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><IMG SRC="image_002.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Dr. Howard Berger:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I'll take that, Per (phon). Well, I think
on the first point here, as far as the integration is concerned, it's proceeding reasonably well and as we anticipated. The number
of centers that we grew in the New York marketplace over the period now of about 15 months was a very substantial undertaking and
one that took us a while to rationalize the assets, as well as make certain that we integrated them in a very prudent manner and
avoided any disruption to the operation. We have the opportunity and have worked on consolidating some centers that we felt were
not necessarily important in terms of the access in that marketplace, and with those closures, there are some costs that we absorbed
relative to personnel and equipment and spaces that do affect the performance. But much of this was anticipated when we acquired
these assets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In a realistic sense, it takes us 9 months
to 12 months of runway to really get these assets performing. All of them need to transition over onto our IT systems, which are
not only the eRAD systems but also our payroll systems, HR systems, accounting systems, etc., and given the size and the magnitude
of these acquisitions, it was something that we had to approach carefully here to make certain we didn't do anything untoward to
the operations. So given the scale and the opportunities that were presented to us in that New York marketplace, I don't think
we've really seen anything that we didn't expect and we're being a little bit more judicious in the integrating of those assets
here.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I believe that they will all not only perform
but exceed performance expectations. We've had some very positive conversations with the payers and the New York marketplace about
setting new rates that I think will substantially impact the Company more in 2017 than they are going to here in the second half
of the year. But the strategy and the rationale for acquiring these assets have never been more apparent and opportunistic to us
than they are at the present time. I think New York is a unique marketplace, not only from a financial standpoint or the financial
world but from a business standpoint, and with opportunities that we have not only in the Imaging but in the Oncology space, particularly
with Breast Link and Breast Disease Management, which is resonating very well with the payers and other providers in that marketplace,
I think will allow us to have some exciting news that will be unfolding here perhaps later this year and the beginning of next
year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a result of the integration, I think
we both see opportunity to further enhance the performance of the operation and it will come not only with improvements, I think,
in margin but also in revenue, both in terms of new contracts, as I talked about before with Capitation opportunities, as well
as improving revenue. It's very clear to us that the conversations that we're having today would only be possible or are only possible
because of the size and position that we've grown very rapidly in that marketplace. We've gone from virtually no centers in the
five boroughs of New York to about 55 centers in that marketplace now in about 3.5 years, and I think the even greater disparity
between hospital reimbursement versus freestanding outpatient facilities is no more evident than it is in that marketplace.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">So, we have the attention, I think, of
a number of players in that marketplace and I'm more excited about the opportunity probably than when we initially embarked on
this 3.5 years ago.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Per Ostlund:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Very good. Thanks for all that color. Dr.
Berger, you also referenced some of the cost and revenue opportunities in yours and Mark's prepared remarks. I think coming out
of the first quarter, you had sort of articulated a $7 million to $10 million target for those opportunities for this year. Does
that sort of range kind of still hold? It sounds, based on your commentary, like it probably does, but just thought I would revisit
that.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Dr. Howard Berger:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Yes. It does. Remember that was a combination
of both East Coast and West Coast opportunities, and the West Coast opportunities have now been pretty much fully realized as of
the second quarter so that the remainder of this year and obviously for the 12 months after July 1, a substantial portion, at least
half of that, will come from the West Coast initiatives and the additional portion of that $7 million to $10 million will come
from East Coast opportunities that are principally going to be implemented here in the third and fourth quarters. So that initiative
is well underway and one that we're very comfortable will come to full fruition for us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><IMG SRC="image_002.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Per Ostlund:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Very good. On that point, I think one of
the revenue opportunities&mdash;and I think this was largely geared to the East Coast&mdash;was the breast tomography side of things.
I'm just kind of wondering&mdash;looking to get maybe a little bit of an update there. I think coming out of the last quarter you
had maybe placed 50, 55 systems, with most of those on the East Coast. Curious to get sort of an update there. I think there's
the reimbursement benefit that's clear and I'm sure there's ample demand for the service. Curious to your thoughts as how you go
to market there because you've got&mdash;with the clustered centers, you probably don't really have to put it everywhere, but just
looking to get your thoughts on that.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Dr. Howard Berger:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Thank you for the opportunity to expand
on that. That has been a tremendous success and adoption of it by the marketplace, and in particular, of the approximately 55 systems
that we have in place right now, 47 of them are on the East Coast. We have scheduled another perhaps 10 or so systems that we hope
to get in place before the end of the year and, principally, perhaps by the October timeframe given Breast Cancer Awareness Month
is October. What we are surprised and delighted with is how rapid the adoption of that has unfolded, particularly and interestingly,
in the Maryland marketplace where the majority of the 47 systems on the East Coast have been allocated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In some of our centers we have converted
up to 60% of our patients to the 3-D tomography capability, both as a result of marketing to our physician referrers that we now
have this capability, as well as more direct marketing to the women whose annual or biannual visits are coming up. Maryland uniquely,
in our centers in the states that we operate in, has adopted more reimbursement for 3-D mammography than any other state. We expect
other states, particularly on the East Coast, to follow shortly with that. But if we do the 3-D mammogram, we either get the reimbursement
from the payer or we get a surcharge from the patient if they elect to have it. With 60% of our women electing it, we are actually
outstripping some of the capacity that we have in some of our centers and, therefore, may need to add additional systems in centers
where we have multiple mammography systems.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">So that has been a huge success for us.
I think the success is also for our female patients that are benefiting from what I believe is a superior technology, and I think
the benefits of that will continue to inure to the Company here in the latter part of this year and going into next year. We are,
as I've stated before, very committed to women's health, particularly with breast disease, and our next big effort to really roll
that out on a larger scale will be in the New York marketplace that could come in combination with a Breast Link initiative that
we are very excited about.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Per Ostlund:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Excellent. Thanks for taking all those
questions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Dr. Howard Berger:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Thank you.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Mark D. Stolper:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Thanks, Par.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><IMG SRC="image_002.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Operator:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Thank you. We'll take our next question
from Juan Molta of B. Riley.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Mr. Molta, please go ahead. Your line is
open.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Juan Molta:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Sorry about that. I was on mute. Hey, good
morning, guys. Could you provide&mdash;you already mentioned you bought back a little bit of debt and paid off some capital lease
obligations. Would you mind providing any update as to what plans are for deleveraging? I know it comes up often, but maybe you
could touch on that a little bit please.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Mark D. Stolper:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Sure. So, during the quarter we paid off
about $9.8 million of our debt, which is a combination of the amortization that we're repaying each quarter on our senior term
loan which will total a little bit over $6 million a quarter, and then additional amortization on our capital leases, which adds
another couple million dollars a quarter given today's&mdash;where we are in the amortization schedules of those pieces of debt.
So, we will continue to do that each quarter. Then in addition, as we've discussed throughout the year, we have not been extremely
acquisitive this year. We will look at opportunistic situations to buy small mom-and-pops at the three to four times EBITDA range
in our existing core markets, but we don't have any real significant acquisitions in the pipeline and so we see more of our free
cash flow accumulating and we expect to have a cash balance at the end of the year, which at that point we can choose to electively
repay some of our first lien with no prepayment penalties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">So, I would suspect this year, for the
remaining part of the year, that on the second and third quarters we'll pay down in the neighborhood of $18 million to $20 million
of debt.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Juan Molta:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Okay. Thank you for that. Next question
is more high level, but since you've mentioned it here in the prepared remarks regarding the Capitation model and this model going
into the post-Affordable Care Act era. Could you provide what your position is on that? You've obviously, at least partially benefited
with volumes from Government-funded exchanges and it seems like some payers don't want to continue with that program. So if you
could simply provide an overall what your position is there, that'd be great.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Mark D. Stolper:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Sure. I mean, we've seen a major expansion
in the last 12 to 18 months of some of the State-run managed Medicaid programs in California. It's called Medi-Cal. Companies like
Molina and Centene and others who have these types of products are taking risk for patient care and therefore are more interested
in contracting with providers who can essentially sub-capitate or where they can syndicate some of that risk to the providers.
So we've benefited, and that's what you saw a lot happen in 2015 where our Capitation book of business increased over 25% versus
2014.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We've also seen an expansion and growth
in the enrollment in existing Capitated arrangements so that more and more of the patients, particularly ones that are now able
to avail themselves of insurance for the first time, are going into these managed products&mdash;HMO products where they've, for&mdash;they've
exchanged a smaller provider network or limited choice for better rates. So we've seen expansion in the numbers that the medical
groups have with whom we contract, and therefore as they bring us more lives, that brings more Capitated dollars to us. They fall
under the existing Capitated arrangements. So of the 12-plus million Americans that have now availed themselves of healthcare for
the first time over the last couple of years, we've seen benefit both on the fee-for-service side, particularly here in California,
which has been where we've seen the highest enrollment and the highest percentage growth in that 12 million patient number, but
also within the Managed programs and our Capitation contracts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><IMG SRC="image_002.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">So, we feel pretty good about continued
growth in our Capitated enrollments. We're always talking to new medical groups and espousing the benefits of Capitated arrangements
versus fee-for-service arrangements, and so we think this will continue to be a growth area for us in California, and then obviously
some of the discussions that we've had this year on the East Coast and bringing that contracting mechanism to the East Coast will
have huge benefits for our East Coast operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Juan Molta:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Okay. All right, very good. We have talked
about previously, I think, Mark, that your exposure to Humana or to Aetna&mdash;I don't remember which one, was not that high&mdash;and
we've seen that some of the commercial players don't want to continue with their exchange program. Do you have any comments on
that on a go-forward?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Mark D. Stolper:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Sure. Our exposure to any one payer is
very, very limited. Our largest payers in virtually all the markets that we operate in, aside from Medicare, are the Blues, Blue
Shield, Blue Cross, administrators. Many of them are unrelated in the markets in which we operate, so Blue Shield is a non-for-profit
here in California, Blue Cross is owned by WellPoint; in Maryland it's CareFirst. So we really have very little national exposure
to any one payer. The fact that some of these larger payers like Humana, which has a higher concentration, frankly, in the Southeast
and in Florida where we're not a player, but the fact that some of these guys are pulling out of the exchange programs really doesn't
affect us at all. In fact, what will happen is many of these patients will just find alternative care or they'll have fewer choices
of health plans to enroll in, but we end up seeing those lives, whether they're in Aetna, United, any of the Blues programs. I
mean, these patients have to go somewhere and in all the markets in which we operate, we contract with all the major payers. So
we have not been concerned with any of the headlines we've seen about some of these larger payers pulling out of these exchanges.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Juan Molta:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Okay. Good. Thank you very much. The other
questions I had have&mdash;you've already addressed them, so thank you very much.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Mark D. Stolper:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Thanks, Juan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Operator:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Thank you. We'll go next to Mitra Ramgopal
of Sidoti.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Mitra Ramgopal:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Yes. Hi. Two questions to follow up on
some of the earlier ones. First, on the quarter, when we look at the increase in operation costs and you talked about potential
margin expansion, I'm just wondering if there was anything in the quarter here that we probably should not be expecting going forward.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Mark D. Stolper:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Yes, hi. Good morning, Mitra. Yes. The
increased operating costs, when you're looking at a comparison versus last year's same period, really results from the Doshi acquisition.
We completed that acquisition in October 1, so with the additional revenue and EBITDA that came from that acquisition, also comes
those costs. So you can't really look at it from an aggregate perspective. Next quarter will be a little bit easier to make that
comparison because of the fact that the Doshi acquisition was completed on October 1, which would be&mdash;actually, I'm sorry;
not next quarter but the fourth quarter the Doshi acquisition will be essentially annualized in our numbers for comparison purposes.
But from the cost savings perspective, we are seeing significant benefits from some of the negotiations we are having with respect
to supplies, particularly around disposables and contrast materials, and that is showing up in our numbers and will continue to
show up for the rest of the year. I think Per asked about our $7 million to $10 million estimate of cost savings, which we articulated
in the first quarter and we're still very confident that we'll get that $7 million to $10 million of cost savings in revenue enhancements
for the year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">So I think, one, to your point or to your
question, it's going to be hard to actually see that in our comparison numbers really until the fourth quarter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Mitra Ramgopal:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Okay. No. Thanks for that color. Then I
had a question with&mdash;coming back in terms of looking at the expansion opportunities. I know you mentioned you're not going
to be looking at acquisitions really later this year, but as we look at 2017 and beyond, and as you sort of look in terms of the
growth initiatives, is the focus going to be more in terms of the joint ventures and partnering with the capitated groups, etc.,
or do you still feel the need in terms of doing more DIG transactions?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Dr. Howard Berger:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Well, I think we have to evaluate these
on a case-by-case basis. The opportunity, should it come about, to enhance our presence in any market that gives us the improved
marketing and operating metrics will be seriously considered. That being said, I believe the opportunities for the Company will
be very much along the lines of joint ventures and Inpatient Radiology opportunities and Capitation, along with our Breast Link
initiatives. But given the opportunities, I think, that are presented to us, we would look at any opportunities to expand or enhance
our presence in an existing marketplace very seriously. But as Mark stated, and I just want to confirm that, we're not looking
at any significant acquisition opportunities for the remainder of this year as we really are focused on integrating all of the
systems and the acquisitions that we did back in 2015 to make certain that the Company is capable of managing to a new level here
with all systems intact.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Mitra Ramgopal:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Just a follow-up on that, as you look to
partner with the capitated groups and other health systems, etc., how much capacity do you think you have on hand that you feel
comfortable handling without having to go out and maybe add more centers?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Dr. Howard Berger:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Well, I think the opportunities that we're
talking about wouldn't necessarily require more centers. If they would&mdash;or if it does, it would be very minimal. I think the
opportunities with the health systems or hospitals are really pretty much with the assets that they currently have right now and
us being able to help manage them and drive opportunities within their existing framework.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Mitra Ramgopal:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Okay. Thanks again for taking the questions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><IMG SRC="image_002.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Mark D. Stolper:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Thanks, Mitra.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Operator:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Thank you. We'll go next to Alan Weber
of Robotti Advisors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Alan Weber:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Good morning. Just, when you talk about
the New York markets, Dr. Berger, you were speaking about kind of the integration is kind of on its way and not fully implemented,
I get it. Can you talk about if you look out two or three years in kind of a flat environment, what does that incrementally mean
to EBITDA or revenue or financially? What does that really mean? How much more is the benefit from the New York integration?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Dr. Howard Berger:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Well, I think it's a complicated answer
because, Alan, I think it involves revenue enhancement opportunities. It involves improving margins, as well as new types of services
that we might offer in a marketplace. For example, we would never have considered bringing Breast Link into the New York marketplace
if we didn't have a very substantial platform of existing, not only imaging centers but the amount of mammography and imaging that
we do related to breast disease is very substantial. So, all of these have to be looked at together, and as we implement our eRAD
system, as we consolidate, as we negotiate better rates with payers, that is a core part of the RadNet strategy regardless of the
market that we're in. I think it happens to be amplified in New York because of the enormous amount of volume that we already see
and which we could potentially increase.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">So I think we have a lot of capacity in
that marketplace, both in terms of the number of sites and potential for further expansion in a number of different ways, but as
I've said before, the ability for us to harvest that really is making certain that we've integrated all of these acquisitions and
can focus on growth opportunities rather than just continuing their integration.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Alan Weber:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Okay. Just as a quick follow-on, when you
talk about the joint ventures, a lot of it, you said, the assets are kind of in place at the hospitals. New York should improve
over time. Is Breast Link&mdash;putting aside any major acquisition, is Breast Link the only significant real investment that you're
going to have to make of capital?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Dr. Howard Berger:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Well, I think we have to make equipment
investment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Alan Weber:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Right. I mean, besides that, right.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Dr. Howard Berger:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Do you mean&mdash;what other kind of investments
are you thinking about?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><IMG SRC="image_002.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Alan Weber:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Well, I mean, you have the footprint in
some of the major markets. You've made the big acquisitions, so going forward to grow EBITDA, is it going to come from joint ventures,
just tuck-in acquisitions, which are not as capital-intensive, is Breast Link significant in the New York markets? Will that require
a significant amount of capital?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Dr. Howard Berger:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Relative to what we spend on equipment,
it's a very small investment. You're dealing mainly with a non-capital-intensive type of business and one that integrates nicely
with existing operations that we have on the Imaging side of it. The Breast Link initiative, if you will, is primarily a physician-driven
opportunity rather than putting a lot of assets in place in order to accommodate that business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Alan Weber:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">So I guess when you look out a few years,
I mean, is capital spending going to be relatively flat or just up a small amount? How do you view that?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Dr. Howard Berger:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Yes. I think it's going to be relatively
flat. The amount of assets that we have and the continued improvement in technology requires us to continue to invest in our facilities,
and some of the newer upgrades that we're looking at, particularly in the area of MRI that can shorten the amount of time that
it takes to do a procedure&mdash;substantially shorten it&mdash;as well as make it more convenient and comfortable for patients
by noise reduction and other tools that are about to be rolled out. It will, I think, give us additional reason to view our capital
investments, not just as maintenance but also as growth opportunities. Given the fact that we have 250 MRI scanners and almost
as many CT scanners, just the turnover on an annual basis and the opportunities that that presents for us will continue to drive
the need for us to invest continually in our centers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This is a technology business and one that
I think will change over a period of time to provide additional opportunities that I think when you look back at them in hindsight
will have proven to be very prudent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Alan Weber:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Okay. Great. Thank you very much.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Dr. Howard Berger:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Thank you, Alan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Operator:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Thank you. That does conclude our question-and-answer
session. I'd like to turn the conference back over for any additional or closing remarks.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Dr. Howard Berger:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Thank you, Operator. Again, I would like
to take the opportunity to thank all of our Shareholders for their continued support and the employees of RadNet for their dedication
and hard work. Management will continue its endeavor to be a market leader that provides great services with an appropriate return
on investment for all Stakeholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Thank you for your time today and I look
forward to our next call. Good day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Operator:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Thank you for your participation. That
does conclude today's conference. You may now disconnect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 15; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" "4 5H# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^_BBBB@ H
MHHH *I7-_;65O-=WT\%G:6\+W%Q=W4R06MO!'AI9KBYEV001QH2[/+(BX!(.
M Q7R#XI?&OPW\.H);;:=;\2B,M;:'9SJ@B9\I%+JUV%:*P@+8E6)F-U)&I98
M0!N'Y1_&;Q_\2?C#=&V\2ZE>76F2W2_V=X-T9)X]&$DOFB"--)MS-/K%TLCJ
M@FOQ>2."-RJ/E8 ^POC9_P %&?@=\+_MNG>&!JGQ4\16?G1M:^%WAM/#D5Q&
M60QWOBF^ M71)!&)#I%MJYVR919'4+7X[_''_@K'^UQXB,UE\.+;P3\([2XE
M:"S&C>'XO&'BME,DT4<<.H^)5U#2I;QF:."3['X;22"42B.&0DE/MWX<?\$Z
M_%GCUK?4_B=J,WP^\/2[9CHEHL-WXQOH54D1R1.)M/T1"=@9[AKJ^C8X-K"0
MWF?I+\(?V5?@+\%/(N? 7P[T*WU^W5"_C+6;:/Q!XQGE"LC2_P#"0ZFLUY9&
M5>);?2CI]FPVA;9 BX /Y0KCX$?\%COVM=\UGXK_ &I1H&IHTG]J>,/BKXA^
M"OA&2SN@-\L&F'6/"MO/82(Y:>#3/#UV;B!GA6(PQ6\:5+7_ (-I/VL/B<T5
M]\6/VGOA]X,-P99+N."_^(GQ1UVUW2%F5Y]3F\.Z?<R-ND D;5IQ")B53@J_
M]J*J5SEMV0!T/;/J3US0B;,\YR .F.F?<^M '\;5K_P:/:-./M.I?\%"?BCH
M.I%_,:Y\#_#*/1&(Q@^5>-\34NE>,$F"0.1%(V\HW0^M:'_P;H_MR?"$6T_[
M/7_!?7]N/P/=V:1Q6FC>)T\9>*?!Z6\+[X;9_#5W\<)=(E@1BA:"73YK8A=G
MD!9?D_K.HH _G;\%_!K_ (.1_P!FI($LOVKOV"_^"AGA739$2;1OCO\ #?QA
M^SA\4=5T_P"56ATOQ9\)]&OO"MKJ,2;Q%?>)HM=\TG?<F=F.WZG\(_\ !3OX
MA?#A4TS_ (*!?L'?M*_L:W%NA34/BUX7TVU_:R_9>79B(WUW\6_V?H?$OB3P
M)IMQ.=Z7GQ0^&G@O2]/LV$FHZRD%M+<1_KTZ;\<@8SU&>N/<>E-\H_WR,%2-
MN5QC.> V#G/1@R^JGL <-\-OBI\-OC'X.TCXB?"?Q[X-^)G@'Q!;BZT'QMX
M\3:-XP\)ZS!EE=]-U_0+R^TV[,+J4G2*X9X)/W<JI(&1>^KYAU/]E7X2Q^,]
M5^*/PZTV;X)?%?7)UO?$7Q ^$)M/!]YXXO4$@2;XI^%[6V;P)\6V599(8KCX
MB^%_$.JZ;!(W]@ZKHUV([R/V_P ,Q^+8;5K+Q?-HNH7MLL:1:]HMO<:=;:PA
M:51//H=U/>2Z1?;462XMX]3U&R+2@V<R*)((@#KZ*** "BBB@ HHHH ****
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M3RIXZ&<U<CR7^U\9">,C4;P6L\/AD_JM7D]JZUJJC[-?[#*L6SD8QCOZYX/
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M4?AAKVK>%8(I7F)D>0Z+8Z3.\C[6E,N_@$8_6VOY.O\ @U0^,<FN_L\?M._
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M$X_;5F/I\'OA_P#^E_BLUT7_  ;^#9^UQ^W",D[OA%^SB?3'_$X^(8]\_?\
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M/$CZ'=>'KAVD."DDK(=T<ID /UOHIJMN+# &WT.<\D>@QTIU !7^?-_P<_\
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M/A[PUXAGUBP;P_J&HVT6FS0>)+>TCBN9DO%N;2Y,D*Q>2\OP=\0?^"ZGPO\
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MLQ_$Z.X:[O-9^$'A'2?$%Q(RM,_BWP=8CP7XN\\*[LLO_"2>'M3<HYWA'3<
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M:Q::73^4?"/PZQF"^DOD7 ^8TN:IPCQAF>.S"-DFL)PG0QF:8>NX7GRJHJ&
MQO(YN5-5?9J<W!5)_P O/[/WP;^.WQW^*F@_#[]F[P?XO\<?%]X=0\0^'-&\
M#:G!H_B>WC\.0#4K[6]+U:YU;0ETR?1HD6^COX]6L[F!D46QEGD2%_TRNO\
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M &4+XOG_ ,P=XY7_ -DS^..V3_;[\5_^27?$O_L0/&/_ *C6K5_$+^PH<_\
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M.L^%_$_A_4H5N--UWP]X@L)=*UO2-0@?Y9[+4],NKJPNX3CS;:YF0,I8,O\
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MEU.;4&DL99)9[F&WC9?*#JX!^'G_  0H_9]/C_XY_%S]JS7K/[1X7^!>F3?
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M%OBB^\67LWBW6=&T;0KR6TN[Y8Y+'3A8>'].6'3(-MK!(LSPJAG<5\>?$O\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
3!1110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  C NH# 2(  A$! Q$!_\0
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M?_\ !27]GCP=XKT'P9X3\'?M'_M :YXK_99^&O[:GAO_ (9O^"6L_%.RU/\
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M]GT%R3A35)8:E[:?.IN\(QARN,(TWS2=3>RLFU?]2V^&_AO _P")#IQSD?\
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MW%M04>96E&4=O><7RJ1[:?AOX<!)71M.!_AVVZY/4XRJY ^]G (SP?O9J/\
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M/#OC?6?&WQCTWPSXOT[6[_Q9HOP<\ ^"+ZQT+2O!VE^#-.^Q3^)M8_09=:F
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ME_I4VG?#B>P\/:-IIU6OUM7Q))D@;R3UX?(/&,_GT'3V&*E'B5P2#OZ'!VD
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MB1/XH\(:A+\3/''AGQ]X'U;P)X0U66*'PSXH\.^)([U-4TF;].AXE( R6Y(
MSG.6)Y(/ &<XQD @$$-4P\2,#DEV);CC()!R<Y!!.2V0?O=">U']A\J2C.LI
M1<I1DM)J<Y*3DKP:OI9)J2M)Z)V:3XNG4E4G-827MU252G.'/"<:$'"G!KVL
M9**OS-J?-*<8M-7FI?G#\2OV5OV^]=?X]_$#1?V@/!.I?'_XN?LL?L&?"?Q%
M\1_#?BOQ'^S]<_$+Q+\!OVA?V@/B=^TOX&\/^)_A[X0U;Q'\!?"7CWX8?%RW
M^%GPO^*'ABRU[QWH%JS:UJ,-OXHM;CQ!+\HZ]_P3"_:D\62?M@:I9^%_@O\
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M+\&>$]2TZ[_:,_9[\01:=XF^"'C"\L;"YO=!U3QGX \1^(IO#M[INE5],?\
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M^'OP=^-'[*WQB_95U+]H3Q-8?"J]_9\^(/CWP#\0? 6I_"+]H;0?V?HSX?\
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M3XCU72K;6=:T3PFGB.ZT"TO;^335^?H?V'_C?X#^"G_!)WQ?\/\ 3OA/XO\
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M-'A_@?*W0=53/X_,.:]+.DW!/%I/G^ZMO.,?AM 'J?SIO]DW/_/I/_WYN/\
MXW5+$3WO+7^[-?J2\#06TJ33;TE.#:^YM'YR_P#!0I1X ^-NA6?@P#P[:^(?
M =MXGUJ'3OW::EX@U'Q5XJ2^U6Y#[RUW<I;0)(X*C;$BJH"@5\(KXZ\7D<Z_
M?GC^^GJ1_<] /RHHKLRNO7_LO#OVU6_LM_:U+^[*K&.O/?11279))6226.>Y
M=E_]KYC_ +!@M<1S/_9,-K*4(2DW^YWE*4I2>[E*3;;;;&\=^,%QM\0:@.O2
M1/;_ &*>/'7BXL?^)_?_ '<\.@[-Z)["BBNUUZ_*_P!]5Z_\O:G?_&>+_9^
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M_P#]]IZ,?[GKS2_\)QXMR?\ B?7_ %;_ ):+V''\%%%'UBO_ ,_ZW_@VI_\
M)C_L_ :_[#@]O^@7#]U_TY$_X3KQ=_T'[_UQO3'Y;,4G_"<^+?\ H/7_ /WV
MG_Q%%%;^VK?\_:O_ (,G_P#)$2P&!M'_ &+"=/\ F&H=E_TZ'+XY\7;"?[?U
M#() _>+TSCILQ^.,TI\;^+0?^0]?_P 7_+1>R@C^#UHHIQK5?>_>U/A?VY__
M "17]GY?>/\ L.#^)?\ ,+A^_P#UY$/CGQ<K'&OZ@.G_ "T7T_W/>E_X3KQ?
MNQ_;^H8SC_6+TSC^Y^O6BBL)5Z_N_OJWPK_E[4_^3">7X!<UL#@UOMA<.NO_
M %Y&#QWXO.T'7[\A@Q(+H<D+G/,?J!^5./C?Q8!QKM\,'CYTXY;I\GL***7U
MBO\ \_ZW_@VI_P#)B6 P'+?ZE@[\ZU^JX>^\^OLAO_"<^+O^@]?_ /?:?_$4
M'QSXM/77K\_5T/\ [)116WMJO_/VI_X'/_Y(B. P/,O]BPG7_F&H?WO^G0W_
M (3;Q7_T'+W_ +ZC_P#C=._X3?Q60<ZY>\?,.8^#P,C]WQP3T[G/7FBBL?K%
M?_G_ %O_  ;4_P#DQRP&!5[8+"+5_P#,-0_E7_3H;_PFWBO_ *#E[_WU'_\
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M\Q.7_OS;#^4%%%;>UJZOVE2_^.7?_$5/!X3E?^RX;I_RXH]_^O8I\6^(N/\
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L6>(03_Q,I.I_Y8VW_P 8HHI^UJ_\_)_^!R_S#ZGA/^@7#?\ @BC_ /*S_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
